5 types of drug-eluting stents including zotarolimus-eluting stent with biolinx polymer show the similar clinical outcomes for the treatment of ST-segment elevation myocardial infarction

초록

Background There were no published data regarding the clinical efficacy and safety of second generation drug-eluting stent (zotarolimus-eluting stent with biolinx polymer, ZES-BP, Endeavor resolute) following primary percutaneous coronary intervention (PCI) in ST-elevation myocardial infarction (STEMI). We evaluated the one-year outcome of zotarolimus-eluting stent with biolinx polymer versus to 1st generation (sirolimus-eluting stent, SES and paclitaxel-eluting stent, PES) and 2nd generation (zotarolimus-eluting stent, ZES and everolimus-eluting stent, EES) drug-eluting stents(DES) for the treatment of STEMI. Methods A prospective, open-labeled, multi-center cohort has been performed. The primary endpoint was major adverse cardiac event (MACE): the composite of cardiac death (CD), recurrent MI and ischemia-driven target vessel revascularization (TVR) at 1 year. Stent thromboses (ST) by ARC definition were analyzed. Results Total 975 patients (ZES-BP=178, EES=197, ZES=203, SES=203, PES=194) were analyzed. One-year MACE were 3.4%, 2.0%, 5.9%, 3.4% and 5.7% in ZES-BP, EES, ZES, SES and PES group, respectively (p=ns). Cardiac death were 2.3%, 1.0%, 2.5%, 1.5% and 1.0% in ZES-BP, EES, ZES, SES and PES group, respectively (p=ns).